A phase 1/2, open-label study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as monotherapy and in combination, in patients with advanced KRAS G12D-mutant solid tumors

Disease:

Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS

Study phase:

Physician name:

David Sanghyun Hong

Department:

Investigational Cancer Therapeutics

For general questions about clinical trials:

1-877-632-6789